ABSTRACT
It is well established that patients with primary antibody deficiency benefit from regular parenteral immunoglobulin replacement with a reduction in bacterial infections, antibiotic requirements, and improved quality of life (34,35). Patients with hypogammaglobulinemia secondary to CLL and multiple myeloma should logically respond in a similar fashion.
